Update on targets of biologic therapies for rheumatoid arthritis

Current Rheumatology Reviews

Volumn 4, Issue 4, 2008, Pages 246-253

  Rasheed, Zafar ^a   Haqqi, Tariq M ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Cytokines; Rheumatoid arthritis; Signal transduction

Indexed keywords

CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR; PROTEIN C JUN; TUMOR NECROSIS FACTOR;

ARTICLE; BIOLOGICAL THERAPY; COMORBIDITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAPK SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 67649643011     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339708786263915     Document Type: Article

References (106)

1. Tarner IH, Muller-Ladner U, Gay S. Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheum 2007; 3: 336-45.
2. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
3. McInnes IB, Liew FY. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheum 2005; 1: 31-9.
4. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4(Suppl 3): S233-S42.
5. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461-8.
6. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120-6.
7. Narimatsu M, Maeda H, Itoh S, et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol 2001; 21: 6615-25.
8. Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: 1282-9.
9. Zimmerman MA, Selzman CH, Cothren C, et al. Diagnostic Implications of C-Reactive protein. Arch Surg 2003; 138: 220-4.
10. Metz S, Wiesinger M, Vogt M, et al. Characterization of the interleukin (IL)-6 inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine binding proteins. J Biol Chem 2007; 282: 1238-48.
11. Study to assess the effect of tocilizumab plus methotrexate on signs and symptoms in patients with moderate to severe active rheumatoid arthritis. [http://www.clinicaltrials.gov/ct/show/NCT 00106548?order =1] (accessed 28 March 2007).
12. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, doubleblind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-50.
13. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized antiinterleukin-6 receptor antibody: a multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-9.
14. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17: 19-49.
15. Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin Rheumatol 2006; 25: 448-52.
16. McInnes IB, Al-Mughales J, Field M, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2: 175-82.
17. Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164: 2832-8.
18. Asqith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheum 2007; 19: 246-51.
19. Ruchatz H, Leung BP, Wei XQ, et al. Soluble IL-15 receptor α-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998; 160: 5654-60
20. Kim YS, Maslinski W, Zheng XX, et al. Targeting the IL-15receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayedtype hypersensitivity. J Immunol 1998; 160: 5742-8.
21. Ferrari-Lacraz S, Zanelli E, Neuberg M, et al. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collageninduced arthritis. J Immunol 2004; 173: 5818-26.
22. Asqith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheum 2007; 19: 246-51.
23. McInnes I, Martin R, Zimmerman-Gorska I, et al. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; (50 Suppl): S241.
24. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005; 52: 2686-92.
25. Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kB-and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004; 6: R120-8.
26. Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs 2003; 4: 572-7.
27. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
28. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007; 179: 4135-41.
29. Kalb JK, Linden A. Interleukin 17 family members and information. Immunity 2004; 21: 467-76.
30. Kim HR, Cho ML, Kim KW, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kB and p38 MAPK dependent signaling pathways. Rheumatology 2007; 46: 57-64.
31. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
32. Stamp LK, James MJ, Cleland LG. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol 2004; 82: 1-9.
33. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002; 46: 802-5.
34. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing antimurine interleukin-17 antibody after the onset of collagen induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-9.
35. Koenders MI, Lubberts E, van de Loo FA, et al. Interleukin-17 acts independently of TNF-α under arthritic conditions. J Immunol 2006; 176: 6262-9.
36. Rohn TA, Jennings GT, Hernandez M, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006; 36: 2857-67.
37. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963-70.
38. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.
39. Wraith DC. Anticytokine vaccines and the immunotherapy of autoimmune diseases. Eur J Immunol 2006; 36: 2844-8.
40. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
41. Mukhopadhyay A, Ni J, Zhai Y, Yu G-L. Aggarwal BB. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274: 15978-81.
42. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-8.
43. Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000; 192: 1677-84.
44. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006; 20: 915-28.
45. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
46. Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.
47. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS over expression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest 2002; 109: 59-68.
48. Wang H, Marsters SA, Baker T, et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 632-7.
49. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
50. Cohen SB. Updates from B cell trial: Efficacy. J Rheumatol Suppl 2006; 77: 12-7.
51. Sweeney SE, Firestein GS. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 231-7.
52. Hammaker D, Sweeney SE, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 2): ii86-9.
53. Hommes DW, Peppelenbosch MP, von Deventer SJH. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003; 52: 144-51.
54. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-2.
55. Saman A, Ronald M. Mitogen-activated protein kinases. Crit Care Med 2002; 30: S74-9.
56. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN Nterminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-2.
57. Fijen J, Zijlstra J, De Boer P, et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogenactivated protein kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001; 124: 16-20.
58. Chabaud-Riou M, Firestein GS. Expression and activation of mitogenactivated protein kinase kinases-3 and-6 in rheumatoid arthritis. Am J Pathol 2004; 164: 177-84.
59. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1: 94-7.
60. Inoue T, Hammaker D, Boyle DL, Firestein GS. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J Immunol 2005; 174: 4301-6.
61. Pargellis C, Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Investig Drugs 2003; 4: 566-71.
62. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-46.
63. Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 2004; 63: 1453-9.
64. Baldassare JJ, Bi Y, Bellone CJ. The Role of p38 mitogen-activated protein kinase in IL-1β transcription. J Immunol 1999; 162: 5367-73.
65. Campbell J, Ciesielsk CJ, Hunt AE, et al. A novel mechanism for TNF-α regulation by p38 MAPK: Involvement of NF-kB with implications for therapy in rheumatoid arthritis. J Immunol 2004; 173: 6928-37.
66. Johansen C, Funding AT, Otkjaer K, et al. Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPKactivated protein kinase 2. J Immunol 2006; 176: 1431-8.
67. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR 167653. Arthritis Rheum 2003; 48: 2670-81.
68. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappaB ligand (RANKL). J Biol Chem 2000; 275: 31155-61.
69. Li X, Udagawa N, Itoh K, et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002; 143: 3105-13
70. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297-303.
71. Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC. IL-1-and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol 2002; 187: 294-303.
72. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology 2008; (PMID: 18187523).
73. Smit RJ. Therapies for rheumatoid arthritis; hope springs eternal. Drug Discov Today 2005; 10: 1598-6.
74. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006; 65: iii83-8.
75. Han Z, Boyle D, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73-81.
76. Han Z, Chang L, Yamanishi Y, et al. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 818-23.
77. Sundarrajan M, Boyle DL, Chabaud-Riou M, et al. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 2003; 48: 2450-60.
78. Inoue T, Hammaker D, Boyle DL, Firestein GS. Regulation of JNK by MKK7 in fibroblast-like synoviocytes. Arthritis Rheum 2006; 54: 2127-35.
79. Zeliadt NA, Warmka JK, Winston SE, et al. Tumor promoter-induced MMP-13 gene expression in a model of initiated epidermis. Biochem Biophys Res Commun 2004; 317: 570-7.
80. Ikeda F, Nishimura R, Matsubara T, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114: 475-84.
81. Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NFkappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001; 276: 8836-40.
82. Lacey D, Sampey A, Mitchell R, et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003; 48: 103-9.
83. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999; 291: 124-30.
84. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-9.
85. Cruz CD, Neto FL, Castro-Lopes J, McMahon SB, Cruz F. Inhibition of ERK phosphorylation decreases nociceptive behavior in monoarthritic rats. Pain 2005; 116: 411-9.
86. Bender K, Gottlicher M, Whiteside S, Rahmsdorf HJ, Herrlich P. Sequence DNA damage-independent and-dependent activation of NF-kB by UV. EMBO J 1998; 17: 5170-81.
87. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kB in rheumatoid synovium: localization of p50 and p 65. Arthritis Rheum 1995; 38: 1762-70.
88. Aupperle K, Bennett B, Han Z, et al. NF-kB regulation by IkB kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001; 166: 2705-11.
89. Nagineni CN, Kutty RK, Detrick B, Hooks JJ. Inflammatory cytokines induce intercellular adhesion molecule-1 (ICAM-1) mRNA synthesis and protein secretion by human retinal pigment epithelial cell cultures. Cytokine 1996; 8: 622-30.
90. Tak PP, Gerlag DM, Aupperle KB, et al. Inhibitor of nuclear factor kB kinase βis a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897-901.
91. Andreakos E, Smith C, Kiriakidis S, et al. Heterogeneous requirement of IkB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis. Implications for therapy. Arthritis Rheum 2003; 48: 1901-12.
92. Kishore N, Sommers C, Mathialagan S, et al. A selective IKK-2 inhibitor blocks NF-kB-dependent gene expression in interleukin-1k-stimulated synovial fibroblasts. J Biol Chem 2003; 278: 32861-71.
93. McIntyre KW, Shuster DJ, Gillooly KM, et al. A highly selective inhibitor of IkB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003; 48: 2652-9.
94. Sharma S, TenOever BR, Grandvaux N, et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003; 300: 1148-51.
95. Kravchenko VV, Mathison JC, Schwamborn K, et al. IKKi/IKKε plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 2003; 278: 26612-9.
96. Aupperle KR, Yamanishi Y, Bennett BL, et al. Expression and regulation of inducible IkappaB kinase (IKK-i) in human fibroblastlike synoviocytes. Cell Immunol 2001; 214: 54-9.
97. Brown C, Gaspar J, Pettit A, et al. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem 2004; 279: 12794-803.
98. Grall F, Gu X, Tan L, et al. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor α in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003; 48: 1249-60.
99. Han M, Kim J, Park B, et al. NF-kB-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis. J Leukoc Biol 2003; 73: 525-9.
100. Elliott S, Coon C, Hays E, et al. Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum 2002; 46: 3230-9.
101. Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-kB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 2000; 12: 1469-79.
102. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kB-differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000; 43: 801-11.
103. Jovanovic DV, Martel-Pelletier J, Di Battista JA, et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages-a possible role in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1134-44.
104. Lee FS, Hagler J, Chen ZJJ, Maniatis T. Activation of the I-kBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997; 88: 213-22.
105. Tuosto L, Costanzo A, Guido F, et al. Mitogen-activated kinase kinase kinase 1 regulates T cell receptor-and CD28-mediated signaling events which lead to NF-kB activation. Eur J Immunol 2000; 30: 2445-54.
106. Kempiak SJ, Hiura TS, Nel AE. The Jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the IκB kinase cascade. J Immunol 1999; 162: 3176-87.